TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16650054
Drug: Fluticasone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone (200 mcg) with levocetirizine
Study: 3513346
Drug: Imipenem and
Normalized name: imipenem and cilastatin
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Imipenem and cilastatin sodium 500 mg every six hours
Study: 29261010
Drug: Chlorogenic acid
Normalized name: chlorogenic acid
DrugBank: Chlorogenic Acid (DB12029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorogenic acid (400 mg three times per day for 12 weeks)
Study: 26892582
Drug: 100mcg vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mcg vitamin K2 (MK7 subtype) daily for 6 months
Study: 4059292
Drug: benserazide/l‐dopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: benserazide/l‐dopa
Study: 6399888
Drug: Amiloride 5
Normalized name: amiloride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride 5 mg
Study: 31981516
Drug: Riluzole 50
Normalized name: riluzole 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole 50 mg
Study: 24681228
Drug: 60 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 μg HB vaccine formulation
Study: 24681228
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg HB vaccine formulation
Study: 24681228
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg HB vaccine formulation
Study: 16093465
Drug: Daily parathyroid
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily parathyroid hormone (1-34) subcutaneously
Study: 10077715
Drug: Anthroposophical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthroposophical therapy
Study: 10077715
Drug: Mainstream medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mainstream medicine (control group)
Study: 31128485
Drug: Non-Traditional Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Traditional Chinese Medicine (non-TCM)
Study: 8511728
Drug: Salbutamol 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol 0.5% solution by nebuliser
Study: 29151179
Drug: Twelfth subcostal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twelfth subcostal nerve block with 10 ml lidocaine 2% + intramuscular diclofenac sodium 45 min before ESWL
Study: 29151179
Drug: Twelfth subcostal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twelfth subcostal nerve block with 10 ml of lidocaine 2% + tramadol at 1 mg/Kg of weight, 45 min before ESWL
Study: 26837628
Drug: Vaginal ring
Normalized name: NuvaRing Vaginal Ring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal ring containing dapivirine, maraviroc, or both drugs for 28 days
Study: 23732051
Drug: Flucloxacillin 500
Normalized name: cloxacillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flucloxacillin 500 mg four times daily (monotherapy)
Study: 23732051
Drug: Flucloxacillin 500
Normalized name: cloxacillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flucloxacillin 500 mg four times daily and phenoxymethylpenicillin 500 mg four times daily (dual therapy)
Study: 18378520
Drug: Ramipril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (10 mg per day)
Study: 18378520
Drug: Telmisartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (80 mg per day)
Study: 8311283
Drug: 3% gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% gelatin in electrolyte solution
Study: 24351518
Drug: NSAID therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID therapy
Study: 31563386
Drug: Sham taping
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham taping with NSAID therapy
Study: 27154871
Drug: Modified Qing'e
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Qing'e Pill (MQEP)
Study: 27992268
Drug: CHOP chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHOP chemotherapy
Study: 10845730
Drug: Placebo to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Levetiracetam 4000 mg daily
Study: 10845730
Drug: Levetiracetam 2000
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam 2000 mg daily (initiated)
Study: 10845730
Drug: Open-label phase
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label phase (Levetiracetam 4000 mg daily)
Study: 3513587
Drug: Progesterone vaginal
Normalized name: progesterone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone vaginal suppositories (200 mg in polyethylene glycol base), self-administered twice daily for a minimum of 12 days before menstruation for 3 months
Study: 3513587
Drug: Placebo, self-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, self-administered twice daily for a minimum of 12 days before menstruation for 3 months
Study: 22704229
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic Acid (TNA) administered preoperatively (1 g 10 minutes before surgery)
Study: 22704229
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic Acid (TNA) administered postoperatively
Study: 22704229
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no TNA administration)
Study: 14989442
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) at 5 ppm
Study: 11897289
Drug: Qualitative descriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualitative descriptions of drug side-effects
Study: 11897289
Drug: Quantitative descriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quantitative descriptions of drug side-effects
Study: 14980334
Drug: Prochlorperazine 10
Normalized name: prochlorperazine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine 10 mg i.v.
Study: 9660282
Drug: Ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg i.v.
Study: 8073244
Drug: Hypnosis administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnosis administered by nurses
Study: 8073244
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral medication combined with nerve blocks and/or spinal administration of drugs
Study: 2817597
Drug: LY171883 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY171883 600 mg twice a day
Study: 4901346
Drug: Ferro-Gradume (slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferro-Gradume (slow-release preparation of ferrous sulphate)
Study: 28325784
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1,100 mg myo‐inositol, 27.6 mg D‐chiro‐inositol, and 400 μg folic acid
Study: 28325784
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg folic acid only
Study: 16984988
Drug: Octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide LAR (20 mg)
Study: 16972594
Drug: Standard (basic)
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard (basic) therapy
Study: 8742957
Drug: rHuEpo therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEpo therapy during dialysis
Study: 31889508
Drug: Daily multiple
Normalized name: Daily Multiple Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily multiple micronutrient powders (MNP; 10 mg zinc, 6 mg iron, and 13 other micronutrients)
Study: 24972577
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine (CM) decoction based on syndrome differentiation
Study: 17894656
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (20 mg/kg/day)
Study: 2593866
Drug: Topical 17
Normalized name: salicylic acid topical 17% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 17 beta-oestradiol (E2) applied twice daily for 45-50 days at concentrations of 0.1 mg/g and 1.0 mg/g
Study: 2593866
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied twice daily for 45-50 days
Study: 23990646
Drug: Behavioral activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral activation treatment for depression (BATD)
Study: 30925498
Drug: Add-on citalopram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on citalopram (30 mg/d)
Study: 25758426
Drug: Partially hydrolyzed
Normalized name: Human Skin Proteins, Partially Hydrolyzed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially hydrolyzed whey formula with L reuteri (PRO)
Study: 25758426
Drug: Partially hydrolyzed
Normalized name: Human Skin Proteins, Partially Hydrolyzed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partially hydrolyzed whey formula without L reuteri (CON)
Study: 15037526
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (100 mg/d)
Study: 10348415
Drug: New therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: New therapy
Study: 16272869
Drug: Standard antituberculous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antituberculous chemotherapy for 6 or 12 months
Study: 2405506
Drug: HCG injections
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCG injections and Placebo injections
Study: 6159391
Drug: Somatostatin (0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (0.025 mg/h)
Study: 30307720
Drug: Conventional dental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dental implants
Study: 19075276
Drug: Low-dose 13-cis
Normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose 13-cis retinoic acid (13cRA)
Study: 7904106
Drug: Calcipotriol ointment
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol ointment (50 micrograms/g)
Study: 9158266
Drug: Coal tar/2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coal tar/2% allantoin/0.5% hydrocortisone cream
Study: 3284406
Drug: Buprenorphine (0.008
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.008 mg/kg)
Study: 3284406
Drug: Morphine (0.333
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.333 mg/kg)
Study: 11475719
Drug: Ticlid 250
Normalized name: Ticlid 250mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlid 250 mg orally, once a day
Study: 11475719
Drug: Panax notoginseng
Normalized name: PANAX NOTOGINSENG TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panax notoginseng (PNG) 8 ml in 250 ml of normal saline intravenous drip once a day
Study: 2612535
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal 16 g/day
Study: 2612535
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal 32 g/day
Study: 2612535
Drug: Cholestyramine 16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine 16 g
Study: 26042589
Drug: Tildrakizumab 5
Normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tildrakizumab 5 mg
Study: 22375409
Drug: Kangai injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangai injection plus FLAG regimen
Study: 19114859
Drug: Injections in
Normalized name: Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections in the previous 3 months
Study: 14557887
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment for infections, allergies, gastroesophageal reflux, and environmental irritants.
Study: 24095300
Drug: Trastuzumab (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (4 mg/kg load, then 2 mg/kg intravenously weekly until surgery)
Study: 24095300
Drug: Lapatinib (1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (1250 mg orally daily until surgery)
Study: 24095300
Drug: Weekly trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly trastuzumab plus lapatinib (750 mg orally daily until surgery)
Study: 15153818
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of fibrin (Group 2)
Study: 10955016
Drug: CSE inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSE inhibitors
Study: 8636309
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg finasteride daily for 6-18 days (group 1)
Study: 8423429
Drug: Chiropractic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic treatment including side-lying manipulation (n = 17)
Study: 3616852
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g im daily for two days)
Study: 3616852
Drug: Ceftriaxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (2 g im daily for five days)
Study: 3616852
Drug: Benzathine penicillin
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzathine penicillin (2.4 X 10(6) units in a single im injection)
Study: 23560500
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg oral gabapentin
Study: 24079752
Drug: Adjuvant S‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant S‐1 therapy
Study: 3462014
Drug: Saline inhalation
Normalized name: Broncho Saline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline inhalation
Study: 12459670
Drug: Dyclonine inhalation
Normalized name: DYCLONINE
DrugBank: Dyclonine (DB00645)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dyclonine inhalation
Study: 11374600
Drug: Ropivacaine inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine inhalation
Study: 12459670
Drug: Lidocaine inhalation
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine inhalation
Study: 9039247
Drug: Inhaled frusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled frusemide (38.0 (6.4) mg, pH = 9)
Study: 2899239
Drug: Inhaled frusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled frusemide
Study: 8381758
Drug: Morphine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (100 micrograms/kg iv)
Study: 8381758
Drug: Naloxone (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.8 mg iv)
Study: 9541446
Drug: Chloramphenicol eye
Normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloramphenicol eye ointment
Study: 29361468
Drug: Neoadjuvant plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant plus adjuvant dabrafenib and trametinib (8 weeks of neoadjuvant oral dabrafenib 150 mg twice per day and oral trametinib 2 mg per day followed by surgery, then up to 44 weeks of adjuvant dabrafenib plus trametinib starting 1 week after surgery for a total of 52 weeks of treatment)
Study: 29361468
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (upfront surgery and consideration for adjuvant therapy)
Study: 1563120
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (for boys with initial growth velocity below mean of healthy control group)
Study: 1563120
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (for boys with initial growth velocity normal)
Study: 3161613
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of MPA daily (Group 1)
Study: 3161613
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of MPA (Group 2)
Study: 26283739
Drug: Liraglutide (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (titrated to a maximum dose of 1.8 mg)
Study: 17548781
Drug: Olanzapine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (1 to 20 mg/d)
Study: 11699044
Drug: Highly active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly active antiretroviral therapy (HAART) including AZT or D4T plus 3TC and either IND, NELF, RITV, or SAQ at standard dosage
Study: 3675893
Drug: Paper prosthesis
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper prosthesis treatment group
Study: 28755971
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate tablet (200mg)
Study: 15003079
Drug: Pindolol, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol, 2.5 mg t.i.d.
Study: 15003079
Drug: Sham augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham augmentation (Control)
Study: 11716199
Drug: Budesonide Easyhaler
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide Easyhaler and Turbuhaler (both doses)
Study: 26066651
Drug: Intensive handwashing
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive handwashing promotion (soap and daily handwashing promotion)
Study: 19169852
Drug: Aspirin after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin after endovascular coiling
Study: 19169852
Drug: Aspirin after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin after neurosurgical clipping
Study: 9394693
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Zn/d (zinc supplementation)
Study: 2431864
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg oral dose of cocaine hydrochloride
Study: 28177714
Drug: High-protein intake
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein intake (HiPROT) at 1.45 g protein/(kg body mass·day) plus 0.72 g branched-chain amino acids per day during BR
Study: 28177714
Drug: Control (CON)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (CON) group receiving 1 g/(kg body mass·day) dietary protein
Study: 23263742
Drug: Casein hydrolysate
Normalized name: casein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein hydrolysate solution (PRO) - 20 g before, 10 g during, 20 g post-exercise
Study: 16877725
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (EPO) 600 units/kg to 900 units/kg, administered intravenously once-weekly for 16 weeks
Study: 12969089
Drug: Tetracycline 500
Normalized name: oxytetracycline 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline 500 mg q.d.s., metronidazole 500 mg t.d.s., bismuth salt 120 mg q.d.s., rabeprazole 20 mg b.d. for 7 days (7TMBR)
Study: 12969089
Drug: Tetracycline 500
Normalized name: oxytetracycline 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline 500 mg q.d.s., metronidazole 500 mg t.d.s., bismuth salt 120 mg q.d.s., rabeprazole 20 mg b.d. for 14 days (14TMBR)
Study: 10883418
Drug: Fasting treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting treatment
Study: 1530028
Drug: Exogenous human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exogenous human chorionic gonadotropin 5000 IU administered intramuscularly on luteal day 0 (group II)
Study: 1530028
Drug: Exogenous human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exogenous human chorionic gonadotropin 5000 IU administered intramuscularly on luteal day +8 (group III)
Study: 31181357
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 300,000 IU vitamin D before surgery
Study: 25498218
Drug: Immediate chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate chemotherapy
Study: 22180399
Drug: Delayed chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed chemotherapy
Study: 15155323
Drug: Droperidol (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (placebo capsule preoperatively and IV droperidol 0.625 mg before induction)
Study: 15155323
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dimenhydrinate LA and droperidol
Study: 11379334
Drug: amoxicillin, clarithromycin
Normalized name: Lansoprazole, Amoxicillin, Clarithromycin KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxicillin, clarithromycin and rabeprazole
Study: 9672795
Drug: PGTP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGTP with adjunctive subconjunctival 5-fluorouracil (5.0 +/- 1.3 injections of 5 mg each, total of 24.8 mg)
Study: 9209607
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg/kg at 50 seconds
Study: 9209607
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg/kg at 60 seconds
Study: 1662637
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg once daily for 3 days (Group I)
Study: 15316710
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg diazepam
Study: 7781487
Drug: Carbomer gel
DrugBank: Carbomer (DB15649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbomer gel Lubrithal (Leo viscous eye gel)
Study: 24257969
Drug: Early once‐daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early once‐daily physical therapy plus a novel, progressive, twice‐daily cognitive therapy protocol
Study: 24257969
Drug: Early once‐daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early once‐daily physical therapy